Literature DB >> 31670618

Metformin: Up to Date.

Silvia Sciannimanico1, Franco Grimaldi1, Fabio Vescini1, Giovanni De Pergola2, Massimo Iacoviello3, Brunella Licchelli4, Edoardo Guastamacchia4, Vito A Giagulli4, Vincenzo Triggiani4.   

Abstract

BACKGROUND: Metformin is an oral hypoglycemic agent extensively used as first-line therapy for type 2 diabetes. It improves hyperglycemia by suppressing hepatic glucose production and increasing glucose uptake in muscles. Metformin improves insulin sensitivity and shows a beneficial effect on weight control. Besides its metabolic positive effects, Metformin has direct effects on inflammation and can have immunomodulatory and antineoplastic properties. AIM: The aim of this narrative review was to summarize the up-to-date evidence from the current literature about the metabolic and non-metabolic effects of Metformin.
METHODS: We reviewed the current literature dealing with different effects and properties of Metformin and current recommendations about the use of this drug. We identified keywords and MeSH terms in Pubmed and the terms Metformin and type 2 diabetes, type 1 diabetes, pregnancy, heart failure, PCOS, etc, were searched, selecting only significant original articles and review in English, in particular of the last five years.
CONCLUSION: Even if many new effective hypoglycemic agents have been launched in the market in the last few years, Metformin would always keep a place in the treatment of type 2 diabetes and its comorbidities because of its multiple positive effects and low cost. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Metformin; heart failure; insulin resistance; polycystic ovary syndrome; type 1 diabetes; type 2 diabetes.

Mesh:

Substances:

Year:  2020        PMID: 31670618     DOI: 10.2174/1871530319666190507125847

Source DB:  PubMed          Journal:  Endocr Metab Immune Disord Drug Targets        ISSN: 1871-5303            Impact factor:   2.895


  6 in total

1.  Metformin induces mitochondrial remodeling and differentiation of pancreatic progenitor cells into beta-cells by a potential mechanism including suppression of the T1R3, PLCβ2, cytoplasmic Ca+2, and AKT.

Authors:  Ertan Celik; Merve Ercin; Sehnaz Bolkent; Selda Gezginci-Oktayoglu
Journal:  J Physiol Biochem       Date:  2022-07-30       Impact factor: 5.080

2.  Use of oral anti-diabetic drugs and risk of hospital and intensive care unit admissions for infections.

Authors:  Jeeyon Rim; Julia Gallini; Christine Jasien; Xiangqin Cui; Lawrence Phillips; Aaron Trammell; Ruxana T Sadikot
Journal:  Am J Med Sci       Date:  2022-01-22       Impact factor: 3.462

Review 3.  Novel Approaches to Restore Pancreatic Beta-Cell Mass and Function.

Authors:  Alena Welters; Eckhard Lammert
Journal:  Handb Exp Pharmacol       Date:  2022

4.  Endocrine system dysfunction and chronic heart failure: a clinical perspective.

Authors:  Giuseppe Lisco; Vito Angelo Giagulli; Michele Iovino; Roberta Zupo; Edoardo Guastamacchia; Giovanni De Pergola; Massimo Iacoviello; Vincenzo Triggiani
Journal:  Endocrine       Date:  2021-10-28       Impact factor: 3.925

5.  Metformin promotes anticancer activity of NK cells in a p38 MAPK dependent manner.

Authors:  Wenjiao Xia; Xin Qi; Mingfeng Li; Yu Wu; Lulu Sun; Xinglong Fan; Yuan Yuan; Jing Li
Journal:  Oncoimmunology       Date:  2021-10-29       Impact factor: 8.110

Review 6.  New Developments in T Cell Immunometabolism and Therapeutic Implications for Type 1 Diabetes.

Authors:  Mengdi Zhang; Yanyan Zhou; Zhiguo Xie; Shuoming Luo; Zhiguang Zhou; Jiaqi Huang; Bin Zhao
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-10       Impact factor: 6.055

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.